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Abstract
 .Why agonist-induced activation of the nicotinic acetylcholine receptor nAcChoR fails completely in the absence of
cholesterol is unknown. Affinity-purified nAcChoRs from Torpedo reconstituted into 1,2-dioleoyl-sn-glycero-3-phosphati-
dylcholiner1,2-dioleoyl-sn-glycero-3-phosphatersteroid bilayers at mole ratios of 58:12:30 were used to distinguish
between three regions of the membrane where cholesterol might act: the lipid bilayer, the lipid–protein interface, or sites
within the protein itself. In the bilayer, the role of fluidity has been ruled out and certain neutral lipids can substitute for
w  . xcholesterol C. Sunshine, M.G. McNamee, Biochim. Biophys. Acta 1191 1994 59–64 ; therefore, we first tested the
hypothesis that flip-flop of cholesterol across the membrane is important; a plausible mechanism might be the relief of
mechanical bending strain induced by a conformation change that expands the two leaflets of the bilayer asymmetrically.
Cholesterol analogs prevented from flipping by charged groups attached to the 3-position’s hydroxyl supported channel
opening, contrary to this hypothesis. The second hypothesis is that interstitial cholesterol binding sites exist deep within the
nAcChoR that must be occupied for channel opening to occur. When cholesterol hemisuccinate was covalently ‘tethered’ to
the glycerol backbone of phosphatidylcholine, channel opening was still supported. Thus, if there are functionally important
cholesterol sites, they must be very close to the lipid–protein interface and might be termed periannular. q 1998 Elsevier
Science B.V.
Keywords: Acetylcholine receptor; Reconstitution; Gating; Cholesterol
Abbreviations: nAcChoR, Nicotinic acetylcholine receptor; BDH, D-b-Hydroxybutyrate dehydrogenase; DFP, Diisopropyl fluorophos-
phate; DOPA, 1,2-Dioleoyl-sn-glycero-3-phosphate; DOPC, 1,2-Dioleoyl-sn-glycero-3-phosphocholine; PA, Phosphatidic acid; DTT,
 . X XDithiothreitol; EDTA, Ethylenediamine-tetraacetic acid; EGTA, Ethylene glycol-bis b-aminoethyl ether N, N, N , N -tetraacetic acid;
MOPS, 4-Morpholinopropanesulfonic acid; PCP, Phencyclidine; PMSF, Phenylmethylsulfonyl fluoride; Tethered-cholesterol, Oleoyl-2-
 .cholesteryl hemisuccinyl phosphatidylcholine; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; TPS, Torpedo
physiologic saline; TLC, Thin-layer chromatography
) Corresponding author. Fax: q1-617-726-5845; E-mail: k_miller@helix.mgh.harvard.edu
0005-2736r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
 .PII S0005-2736 97 00280-0
( )G.H. Addona et al.rBiochimica et Biophysica Acta 1370 1998 299–309300
1. Introduction
The effect of cholesterol on lipid bilayer structure
is quite well understood, and the structural require-
w xments for action are quite strict 1 . On the other
hand, the modulatory role of cholesterol on mem-
brane proteins has not been explored in detail, and
the mechanisms involved remain obscure; yet, it is
becoming evident that cholesterol may play an impor-
tant modulatory role in disease processes and in drug
action. For example, cholesterol modulates prote-
olytic cleavage of the amyloid precursor protein and
may be involved in the etiology of Alzheimer’s dis-
w xease 2 , it modulates the action of general and local
w xanesthetics on acetylcholine receptors 3,4 , and of
w xneurosteroids on the GABA receptor 5 .A
A priori, there are three regions of the membrane
with which cholesterol might modulate membrane
proteins: in the bilayer, the lipid–protein interface, or
on the protein itself. In the first, the protein’s func-
tion depends on some physical property of the bulk
lipid bilayer such as fluidity. In the second, lipid
properties at the lipid–protein interface, such as acyl
w xchain length or lateral pressure 6 , might be impor-
tant. In the third, allosteric binding sites, specific for
cholesterol would exist on the protein, either in the
 .lipid–protein interface annular or within the protein
 .itself interstitial sites . In the case of the acetyl-
choline receptor, the best understood member of a
family of homologous ligand-gated channels that play
important roles in the central nervous system, phos-
pholipids alone cannot support agonist-induced chan-
w xnel opening in the absence of cholesterol 7 . The
action on the channel does not correlate with modula-
w xtion of lipid fluidity 8,9 , and it has been suggested
that interstitial cholesterol sites may be involved in
w xreceptor activation 10 as they appear to be in the
 2q 2q. w xCa –Mg -ATPase 11 . In the case of rhodopsin,
it has been shown that cholesterol affects both func-
tion and stability. However, it is still unclear whether
the mechanism of cholesterol’s modulation of
w xrhodopsin is based on a bulk lipid property 12 or a
w xdirect interaction with rhodopsin 13 .
Until recently, the kinetic step at which cholesterol
acts during activation of the nAcChoR remained un-
defined. Rapid cation flux measurements are the most
direct way to determine the role of lipids in receptor
w xactivation 14 , but flux kinetics are strictly dependent
on vesicle morphology, which may vary with lipid
w xcomposition 15 . There is no rapid and reliable
method for controlling for variation in vesicle inter-
nal volume and receptor surface density, as well as
w xfor inhomogeneities in the vesicle population 16 .
Furthermore, vesicles are not formed when AcChoR
w xis reconstituted into some lipid bilayers 17,18 .
Therefore, we recently developed an assay using
ethidium bromide fluorescence to probe receptor acti-
w xvation on a rapid time scale 18 . When receptors
were rapidly mixed with agonist plus ethidium, the
earliest fluorescent component was found to report
the fraction of channels that opened and their appar-
ent rate of fast desensitization. Cholesterol was shown
to modulate the channel-opening probability from
zero in the absence of cholesterol, to native values in
the presence of )20 mol% cholesterol, whereas the
rate of fast desensitization was unperturbed. Here, we
use this methodology in nAcChoRs reconstituted with
various cholesterol analogs to locate the site of
cholesterol’s action, and to test models of its mecha-
nism of action.
2. Materials and methods
2.1. Materials
Torpedo nobiliana were obtained live from Biofish
 .Associates Georgetown, MA . All phospholipids
were purchased from Avanti Polar Lipids Alabaster,
. AL , and cholesterol from Calbiochem La Jolla,
.CA . Cholesteryl hemisuccinate and cholesterol 3-
 .sulfate were purchased from Sigma St. Louis, MO .
Cholesteryl phosphorylcholine was purchased from
 .Fluka Ronkokoma, New York . Affigel 102, acryl-
amide, bis-acrylamide, and Coomassie brilliant blue
 .were purchased from Biorad Richmond, CA . Spec-
trarPor tubing for dialysis was obtained from Spec-
 . w3 xtrum Medical Industries Houston, TX . H Acetic
anhydride was obtained from New England Nuclear
 .  .Billerica, MA and dithiothreitol DTT and bro-
moacetyl bromide were purchased from Fisher
 .Biotech Pittsburgh, PA . Choline bromide, ethylene-
 .diamine-tetraacetic acid EDTA , ethylene glycol-
 . X Xbis b-aminoethyl ether N, N, N , N -tetraacetic acid
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 .  .EGTA , phenylmethylsulfonyl fluoride PMSF , and
1 - 5 -d im eth y lam in o n ap h th a len e-1 -su lfo -
.namido ethane-2-trimethylammonium, were pur-
 .chased from Sigma St. Louis, MO and all other
chemicals were obtained from Aldrich Milwaukee,
.WI unless otherwise stated.
Bromoacetylcholine bromide was synthesized from
w xcholine bromide and bromoacetyl bromide 19 .
w3 xH Acetylcholine iodide was synthesized from
w3 xH acetic anhydride and b-dimethylaminoethanol
w x20 . Dns-C -Cho was synthesized as previously des-6
w x   .cribed 21 . 1-oleoyl-2- cholesteryl hemisuccinyl
phosphatidylcholine was synthesized as previously
w xdescribed 11 .The compound was purified by prepar-
ative TLC usingchloroformrmethanolrconcentrated
 .ammoniarwater 5:3:0.3:0.15 vrv as the solvent.
The purified compound ran as a single spot on TLC
with an R of approximately 0.25. Mass spectrome-f
try of the purified compound showed the correct
molecular weight of 990 grmol.
2.2. Preparation of nAcChoR-rich membranes from
Torpedo nobiliana
The nAcChoR-rich membranes were prepared from
w xT. nobiliana following published procedures 22,23 .
The electroplaques were excised from a freshly euth-
anized T. nobiliana that was packed in ice for 1 h.
Each electric organ was cut into small pieces and
approximately 400 g of tissue was pureed in a Cuisi-´
nart with an equal amount of homogenization buffer
containing 0.1 mM PMSF and 10 mM in iodoacet-
amide. The PMSF and iodoacetamide were added to
the buffer just before use. The pureed tissue was then´
homogenized by pulsing for 2=60 s in a Waring
blender. The homogenate was spun in a Sorvall RC
5BrGSA centrifuge for 10 min at 5250 rpm, 48C to
remove connective tissue. The supernatant was fil-
tered through gauze before being spun for 2 h at 9750
rpm, 48C. This supernatant was discarded and the
pellets containing nAcChoR-rich membranes were
combined and resuspended in an equal amount of
buffer A 100 mM NaCl, 10 mM MOPS, 0.1 mM
.EDTA and 0.02% sodium azide, pH 7.4 . The resus-
pended pellets were rapidly frozen in liquid nitrogen
and then stored at y808C.
2.3. Purification and reconstitution of the nAcChoR
using affinity chromatography
Briefly, receptor-rich membranes isolated as de-
scribed above were suspended in buffer A to a final
concentration of 2 mgrml, treated with the acetyl-
choline esterase inhibitor DFP 0.05 ml in 0.95 ml
.ethanol and stirred on ice for 30 min. The suspen-
sion was then pelleted by centrifugation for 1 h at
48C at 41,000 rpm in a Dupont A-641 rotor. The
diisopropyl fluorophosphate-treated crude membranes
were homogenized in buffer A, made to a protein
concentration of 20 mgrml, rapidly frozen in liquid
nitrogen and stored at y808C until needed. The
nAcChoR was purified and reconstituted into lipid
vesicles using a modification of a previously de-
w x scribed procedure 24 . Affi-gel 102 in place of
.Affi-gel 401 was derivatized with DL-N-acetyl
homocysteine thiolactone and then modified with
bromoacetylcholine bromide. The affinity column was
pre-equilibrated with 100 ml of buffer A containing 1
mgrml DOPC and 1% cholate. The crude mem-
branes were solubilized in buffer A containing 2%
sodium cholate at a final protein concentration of 2
mgrml and stirred at 48C for 1 h. The solution was
then centrifuged for 1 h at 41,000 rpm at 48C in a
Dupont A-641 rotor, and the supernatant applied to
the affinity column at a flow rate of 2 mlrmin. The
column was washed with 150 ml of buffer A contain-
ing 1 mgrml DOPC and 1% cholate, then 100 ml of
buffer A containing 2.5 mgrml DOPC and 1%
cholate and allowed to equilibrate overnight to ensure
complete exchange of lipids. The next day, the col-
umn was washed again with 100 ml of buffer A
containing 2.5 mgrml DOPC and 1% cholate, and
then 100 ml of buffer A containing 0.3 mgrml
DOPC and 1% cholate. The nAcChoR was eluted in
100 ml of buffer A containing 1% cholate, 0.3 mgrml
DOPC and 15 mM carbachol. Fractions absorbing at
280 nm were pooled and dialyzed for 48–60 h at 48C
against 2 l of buffer A under a constant nitrogen
purge with a total of 6 buffer changes. After dialysis,
the reconstituted membranes were harvested by cen-
trifugation and rapidly frozen in liquid nitrogen and
stored at y808C.
Re-reconstitution was performed by solubilizing 3
 . mg 1 ml of purified AcChoR previously reconsti-
.tuted in DOPC membranes via detergent dialysis in
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1 ml of buffer A containing 2% cholate 1% final
.concentration and 2 mg of desired lipid, with the
lipid usually in the mole ratio of 58:12:30
DOPCrDOPArsteroid. The solubilized mixture was
then dialyzed as above.
2.4. Characterization of reconstituted nAcChoR
w xProtein concentration 25 , phospholipid content
w x w x26 , and cholesterol content 27 were determined as
previously described. All bilayer compositions are
w xgiven in mol%. SDS-PAGE 28 was performed un-
der denaturing conditions to verify the identity and
purity of the receptor. Two methods were used to
determine the concentration of agonist binding sites.
First, by competition of the fluorescent cholinergic
 .ligand, dansylaminoethyl trimethylammonium per-
w xchlorate, by acetylcholine 29 and second by a
w3 x w xH AcCho binding assay 22 . Receptor concentra-
tion refers to protein unless agonist sites are specified
which would be two agonist sites per oligomer.
2.5. Determination of cholesterol and cholesterol
deri˝ati˝es in re-reconstituted AcChoR samples
The semi-quantitative determination of cholesterol
and cholesterol analogs in reconstituted and re-recon-
stituted membrane preparations was achieved by ex-
traction and TLC identification of the extracted lipids
 .on silica gel G plates Analtech, Newark, DE, USA
in the following solvent system: isopropanol:chloro-
 . w xform:methanol:ammonia, 40:40:20:8 vrv 30 .
Briefly, 0.2 ml samples of reconstituted or re-recon-
stituted membranes were extracted with 0.2 ml of the
TLC solvent for 30 min under constant mixing at
room temperature and then centrifuged for 2 min in
an Eppendorf centrifuge. The liquid phase was trans-
ferred to another tube, evaporated under a stream of
nitrogen, and dissolved in 0.1 ml of the TLC solvent.
Samples of 0.03 to 0.05 ml were spotted on the TLC
plate and the compounds visualized by charring the
plates at 1208C after spraying with 5% potassium
dichromate in 40% sulfuric acid. The R valuesf
found for cholesterol, cholesteryl hemisuccinate
and cholesterol 3-sulfate in isopropanol:chloroform:
methanol:ammonia, 40:40:20:8, vrv were 0.98, 0.57
and 0.66, respectively. Cholesteryl phosphorylcholine
  .and 1-oleoyl-2- cholesteryl hemisuccinyl phos-
phatidylcholine had R values of 0.55 and 0.25,f
respectively, in chloroformrmethanolrconcentrated
 .ammoniarwater 5:3:0.3:0.15 vrv .
2.6. Stopped-flow fluorescence energy transfer assay
The stopped-flow fluorescence energy transfer ex-
periments were performed with a BioSX-17 MV
spectrofluorimeter with a 150-W xenon arc lamp and
a SpectraKinectic monochromator fitted with a
diffraction grating Applied Photophysics, Leather-
.head, England . All experiments were carried out at
 .208C in Torpedo physiologic saline TPS buffer
250 mM NaCl, 5 mM KCl, 3 mM CaCl, 2 mM
MgCl , 5 mM NaH PO , and 0.02% NaN at pH2 2 4 3
. 7.0 . Equal volumes of ethidium plus ligands where
.appropriate and nAcChoR vesicle suspension were
rapidly mixed to give a final receptor concentration
of 0.2 mM, equivalent to 0.4 mM in acetylcholine
binding sites and 0.8 mM ethidium. When a high
agonist concentration was used, 10 mM carbamyl-
choline was always the final concentration. Trypto-
 .phan residues were excited at 290 nm 0.5 mm slit ,
and ethidium fluorescence was recorded with a 530-
nm high bandpass cutoff filter. The electronic filter
was set to 150 ms. Four to eight traces were acquired
digitally for each set of conditions and then signal-
 .averaged. Each trace 2000 data points was acquired
for 100 s with the instrument in a logarithmic time-
base mode. Data collection was continued if the
reaction did not reach equilibrium within this time. A
nonspecific binding trace was always obtained for
each experiment by mixing 0.8 mM ethidium, 10
mM carbamylcholine and 500 mM phencyclidine
with receptor.
3. Results
3.1. Characterization of the nAcChoR
The lipid content of the affinity-purified AcChoR
reconstituted into DOPC was modulated by resolubi-
lizing AcChoR membranes with 1% cholate contain-
ing the desired lipid mixture and then achieving
reconstitution by detergent dialysis. The procedure is
referred to as re-reconstitution. All re-reconstituted
samples were prepared with lipid mole ratios of
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 .58:12:30 DOPCrDOPArsteroid . We chose 30
mol% steroid because receptor activation is maximal
w xabove 20–25% cholesterol 18 . The molar propor-
tion of DOPA was kept constant at 12% of the total
lipid, because this reproduces the average charge
density due to phospholipids in native membranes,
assuming that the average negative charge is 1.5 per
w xmolecule of DOPA 31 . No attempt was made to
compensate for surface charge when using charged
steroids, but this did not seem to affect the results.
This is consistent with our previous observation that
the receptor’s behavior was identical in
DOPCrcholesterol and DOPCrDOPArcholesterol
w xbilayers 18 . The total lipid-to-protein ratios in all of
the samples were approximately 300:1. The structures
of the cholesterol analogs used in this study are
shown in Fig. 1.
Aliquots of all samples containing cholesterol,
cholesteryl hemisuccinate, cholesterol 3-sulfate,
cholesteryl phosphorylcholine and 1-oleoyl-2-
 .cholesteryl hemisuccinyl phosphatidylcholine were
extracted from the re-reconstituted membranes as
described in Section 2 and analyzed by thin layer
chromatography. The only cholesterol analog de-
tected by the cholesterol assay of Rudel and Morris
w x27 was cholesteryl hemisuccinate; the assay was
Fig. 1. The structures of cholesterol analogs used in this study.
All substituents were attached to the 3-position hydroxyl on
 .  .cholesterol where a is cholesterol, b cholesteryl hemisucci-
 .  .nate, c cholesterol sulfate, d cholesteryl phosphocholine and
 .   .e 1-oleoyl-2- cholesteryl hemisuccinyl phosphatidylcholine or
tethered-cholesterol.
Fig. 2. The effect of carbachol on the time-resolved fluorescence
of ethidium rapidly mixed with AcChoR reconstituted in
DOPCrDOPArcholesterol at a mole ratio of 58:12:30. The final
concentration of ethidium, reconstituted AcChoR and carbachol
when used was 0.8 mM, 0.2 mM and 10 mM, respectively.
AcChoR re-reconstituted into membranes containing 30 mol%
 .cholesterol rapidly mixed with ethidium alone lower trace or
 .with 10 mM carbachol upper trace . The inset is AcChoR
 .re-reconstituted in DOPCrDOPA 88:12 rapidly mixed with
ethidium and 10 mM carbachol. All traces were corrected for
nonspecific binding.
thus useful for ruling out the presence of trace
amounts of cholesterol where appropriate. Each of
the samples showed the presence of the expected
quantities of the respective compounds with no traces
of cholesterol. It proved critical to assay for the
presence of native cholesterol in the reconstituted
DOPC membrane preparation because occasionally,
 .native cholesterol 10–15 mol% was found to carry
over into the purified membranes. All experiments
reported here used receptor reconstituted into DOPC
membranes that were verified to have no residual
cholesterol.
3.2. Effects of cholesterol analogs on AcChoR acti˝a-
tion
Fig. 2 shows the time dependence of ethidium
fluorescence corrected for nonspecific binding fol-
lowing rapid mixing of re-reconstituted AcChoR
membranes containing 30 mol% cholesterol with a
solution of ethidium and carbamylcholine to give a
final concentration of 0.8 mM ethidium and 0 or 10
mM carbamylcholine. The early component is appar-
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ent in the first second at 10 but not 0 mM carbamyl-
choline and has a rate of 2.1 sy1 in this single
experiment compared to an average value of 4.7"1.2
sy1 reported previously in the presence of 10 mM
w xcarbamylcholine 18 . As expected, the early compo-
nent was not observed in the presence of 10 mM
carbamylcholine for AcChoR reconstituted into
 .DOPCrDOPA inset, Fig. 2 , nor in the stock Ac-
ChoR reconstituted into DOPC from which all re-re-
 .constituted AcChoR was prepared data not shown .
These latter samples serve as controls for the re-re-
constitution procedures, providing the baseline against
which the effects of added steroid can be assessed.
3.3. Negati˝ely charged cholesterol analogs
Fig. 3a shows the time dependence of ethidium
fluorescence corrected for nonspecific binding fol-
lowing rapid mixing of carbamylcholine plus ethid-
ium with re-reconstituted AcChoR membranes con-
taining 30 mol% cholesteryl hemisuccinate at the
concentrations indicated. The corrected trace with no
agonist present shows no early component, but that
with 10 mM agonist has a clear early component with
Fig. 3. The effect of cholesterol analogs on state transitions of the
AcChoR induced by a saturating concentration of agonist 10
.mM carbachol detected using 0.8 mM ethidium. The final
AcChoR concentration was 0.2 mM. All traces have been nor-
malized to AcChoR re-reconstituted into membranes containing
30 mol% cholesteryl hemisuccinate, which had a fluorescence
 .maximum of 120 mV at 3.0 s. Trace a : AcChoR re-recon-
stituted into membranes containing 30 mol% cholesteryl
 .hemisuccinate, b : AcChoR re-reconstituted into membranes
containing 30 mol% cholesterol 3-sulfate fluorescence maximum
.  .of 131 mV at 3.0 s and c : AcChoR re-reconstituted into
membranes containing 30 mol% cholesteryl phosphorylcholine
 .fluorescence maximum of 51 mV at 3.0 s . All traces were
corrected for nonspecific binding.
Fig. 4. The effect of the tethered-cholesterol, 1-oleoyl-2-
 .cholesteryl hemisuccinyl phosphatidylcholine, on agonist-in-
duced conformation changes detected using 0.8 mM ethidium.
The final AcChoR concentration was 0.2 mM and carbachol
 .concentration 10 mM. Trace a : AcChoR re-reconstituted into
 .membranes containing 30 mol% tethered-cholesterol and b :
AcChoR re-reconstituted into membranes containing 30 mol%
tethered-cholesterol and 30 mol% cholesterol. All traces were
corrected for nonspecific binding.
a rate of 2.3"0.12 sy1. Thus, 30 mol% cholesteryl
hemisuccinate supports rapid agonist-induced confor-
mational changes, a result that is consistent with the
w xcation flux work 32 . When AcChoRs were re-recon-
stituted with 30 mol% cholesterol 3-sulfate, they
underwent agonist-induced structural changes in a
 .similar manner Fig. 3b and with a comparable rate
of fast desensitization of 2.2"0.1 sy1.
3.4. Zwitterionic cholesterol analogs
Fig. 3c shows that when 30 mol% of the zwitteri-
onic steroid, cholesteryl phosphorylcholine, is in-
cluded in the re-reconstituted AcChoR membranes,
high agonist concentrations induce an early compo-
nent of ethidium fluorescence that has an apparent
rate of 2.4"0.08 sy1, confirming the suggestion
from the section above that the nature of the sub-
stituent at the 3-position of cholesterol is of little
importance for receptor activation.
A more dramatic confirmation of the latter conclu-
sion is provided by the analog in which cholesterol is
 tethered to a phospholipid, 1-oleoyl-2- cholesteryl
.hemisuccinyl phosphatidylcholine. When this teth-
ered-cholesterol was re-reconstituted into membranes
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at 30 mol%, it also supported rapid agonist-induced
conformation changes; the early component having
an apparent rate of 3.4"0.2 sy1 very similar to that
 .of cholesterol and its analogs above Fig. 4a . Fur-
thermore, when an additional 30 mol% of cholesterol
was incorporated into this membrane preparation
 .DOPCrDOPArCholrtethered-Chol 28:12:30:30 ,
very similar fluorescence traces were obtained Fig.
.4b .
3.5. A spin-labeled cholesterol analog
The spin-labeled steroid, 3-DOXYL-17b-hydroxy-
5a-androstane, could be incorporated by re-recon-
stitution at up to 12 mol% in DOPCrDOPA nAc-
ChoR membranes. These membranes supported rapid
agonist-induced conformation changes; the early
component having an apparent rate of 2.4"1.4 sy1.
Addition of 30 mol% cholesterol roughly doubled the
amplitude of the early phase without significantly
affecting its rate.
4. Discussion
In this study, we aimed to distinguish between
three regions of the membrane where cholesterol
might have a role in the activation of the nAcChoR:
the lipid bilayer, the lipid–protein interface, and the
protein itself. In each case, we chose the most plausi-
ble mechanistic model consistent with the available
data, and selected cholesterol analogs to distinguish
between these models. We used a morphology-inde-
pendent fluorescence assay based on the channel
blocker ethidium bromide, which reports channel ac-
w xtivation 18 . Use of such assays is in line with other
studies of the role of cholesterol in reconstituted
w x  2qsystems such as rhodopsin 12 and the Ca –
2q. w xMg -ATPase from sarcoplasmic reticulum 11 .
4.1. Does cholesterol act in the bilayer?
First, we considered the lipid bilayer. The role of
w xfluidity has already been discounted 9,32 . Any
model needs to be able to account first for the fact
that in the absence of cholesterol, activation does not
occur, but that it occurs with just a few percent
w xcholesterol 18 , and second for the remarkable obser-
vation that many other neutral ‘lipids’, such as a-
tocopherol, coenzyme Q and vitamins D and K ,10 3 1
w xcan be substituted for cholesterol 32,33 . This sug-
gested to us that cholesterol’s unique ability to rapidly
flip-flop in the membrane from one leaflet to the
w xother might be the key to its action 18 , because this
ability would be shared by the other activation per-
missive ‘lipids’, but not by phospholipids. This hy-
pothesis is only plausible if a mechanism coupling
such a transbilayer motion to the receptor’s function
can be devised. If an agonist-induced conformation
change results in the cross-sectional area of the recep-
tor changing asymmetrically in the bilayer, causing a
differential change in the surface area of each leaflet
of the bilayer, a mechanical bending strain would be
introduced, which would tend to oppose the confor-
mation change. In the absence of cholesterol, the
activation energy might be prohibitive, but the strain
would be readily relieved by a net flux of cholesterol
from the convex to the concave side of the bilayer as
indicated in Fig. 5a. Such a model requires that
cholesterol be able to flip-flop on the submillisecond
time scale. It is well established that cholesterol flips
in the bilayer within the dead time of conventional
w xtechniques 35,36 , and more recent NMR measure-
ments of the flip-flop rates of un-ionized bile salts
allowed an estimate of cholesterol’s flip-flop rate as
3 y1 w x)10 s 37 , which is fast enough to be involved
w xin channel activation 38 .
An argument against this model is that cryoelec-
w xtron microscopy 39 reveals no structural change in
the lipid–protein interface upon activation. However,
the diameter of the oligomeric receptor in the mem-
˚brane is approximately 60 A, with a resolution of
˚ w x;8.7 A 39 , giving a cross-sectional area of about
˚2800 A. The partial molar area in the phospholipid
˚
2 w xbilayer may be as small as 18 A 40 . Each choles-
terol that flips, therefore, causes a differential surface
area change equivalent to approximately 1.25% of the
oligomer’s cross-sectional area.
To test this hypothesis, we used charged choles-
terol analogs, which would not flip across the mem-
brane on the time scale required for activation. First,
as a control for the effects of surface charge, we used
cholesteryl hemisuccinate, a fraction of which should
be uncharged in the lipid–water interface, and there-
fore still able to support activation via the cholesterol
flipping mechanism. When AcChoR was re-recon-
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Fig. 5. Models in which conformation-induced bending strain in the lipid bilayer is relieved by cholesterol. This class of model assumes
that activation of the channel involves a conformational change in which the cross-sectional area of the channel increases in a nonuniform
fashion. This results in a net asymmetric expansion in the two leaflets of the membrane’s bilayer, causing an increase in the mechanical
strain of the bilayer. Relief of the mechanical strain, which can be achieved via two mechanisms, allows the conformation change to
proceed and the channels to open. In both models, the receptor is initially in the resting state with the necessary amount of cholesterol in
 .the bilayer. Upon activation, the induced bilayer stress is relieved in model a by cholesterol molecules rapidly flipping from the upper
 .leaflet to the lower leaflet of the bilayer. In model b , cholesterol binding sites on the receptor became exposed during the conformation
change. The induced bilayer stress is then relieved by cholesterol diffusing laterally to bind to the exposed sites on the receptor,
stabilizing the open state. The cholesterol binding sites would have to rapidly equilibrate with cholesterol, thus be readily accessible from
the lipid–protein interface. For simplicity, only two bound cholesterol molecules are shown, but one within each subunit interface is more
w xlikely 34 .
stituted into DOPCrDOPArcholesteryl hemisucci-
nate at a mole ratio of 58:12:30, the preparation was
found to support agonist-induced conformational
 .changes Fig. 2a , behaving exactly like re-recon-
stituted receptor containing cholesterol as the steroid.
This result is consistent with the slow flux studies
that showed cholesteryl hemisuccinate supported ago-
w xnist-induced cation flux 32 .
The second analog tested was cholesterol-3-sulfate,
which bears a fixed negative charge of two and
should be unable to flip-flop rapidly. Receptor re-re-
constituted with 30 mol% cholesterol 3-sulfate was
found to support receptor activation, exactly like
 .cholesterol itself Fig. 2b . Finally, to eliminate any
unexpected effects of net negative charge, a zwitteri-
onic cholesterol analog, cholesteryl–phosphoryl-
choline, was also found to support receptor activation
 .Fig. 2c . Thus, the ability of these two charged
cholesterol analogs to support channel activation ef-
fectively rules out any model based on cholesterol
flipping from one leaflet of the bilayer to the other.
4.2. Nonannular or interstitial sites
The second region of the membrane we considered
was the receptor protein itself. The importance of
nonannular, or interstitial, sites, sequestered within
the protein, perhaps between subunits, has been em-
w xphasized by Ding et al. 11 . That such sites exist on
the nAcChoR is inferred from studies with bromi-
nated cholesteryl hemisuccinate, which, upon titration
into receptors reconstituted into brominated phospho-
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lipid, causes the intrinsic fluorescence to be further
w xquenched 10,34 . Supporting evidence is: that it is
not possible to remove all the cholesterol from native
membranes when it is repeatedly extracted into lipid
w xvesicles 41 , that receptors have a high affinity for
w xcholesterol in lipid monolayers 42 , and that photoac-
tivatable cholesterol analogs incorporate in the pro-
tein, in some cases in an agonist-sensitive manner
w x14,43 .
Our titration curve of the role of cholesterol in
channel activation correlates with the above intrinsic
fluorescence quenching curves within the rather large
w xexperimental errors 18 . To test the interstitial site
model more rigorously, we synthesized a
w xcholesterol-containing phospholipid 11 , which re-
 .sides at the lipid–protein interface Fig. 1e . This
tethered-cholesterol analog was then re-reconstituted
into inactive DOPCrDOPA nAcChoR membranes
with and without the addition of free cholesterol. The
analog alone restored activity to the inactive prepara-
 .tion Fig. 4 , and, furthermore, the addition of free
cholesterol did not further enhance activity, indicat-
ing that the lipid-linked cholesterol itself had restored
full function. The succinamide arm on the tethered-
cholesterol would allow some access of the steroid
backbone to a binding site, but based on the diameter
˚ .of the receptor in the membrane region ;60 A and
˚ .the length of the spacer arm ;6 A , the outer end of
this site must be close to the lipid–protein interface.
Further, the insensitivity to the size of the substituent
on the 3-position suggests that it does not contribute
to the binding site, and the tolerance for charge also
suggests the head group remains hydrated at the
lipid–protein–water interface. Therefore, occupation
of deeply buried interstitial sites is in no way re-
quired for activation.
This finding for the nAcChoR contrasts with that
 2q 2q.for Ca –Mg -ATPase, where this tethered-
cholesterol analog was first used to establish the
 2q 2q.presence of interstitial sites in Ca –Mg -ATPase
w x11 . In this protein, tethered-cholesterol did not sup-
port activity, which was only restored in the presence
of free cholesterol.
4.3. Sites in the lipid–protein interface
Although the above evidence rules out interstitial
sites, it is quite consistent with cholesterol sites lo-
cated in the lipid–protein interface. Agonist binding
induces its conformation change over tens of
angstroms, probably causing an extensive conforma-
tion change in the receptor. Recent work points to the
participation in gating of at least the M1, M2 and M4
w xhelices and probably other regions 38,44 . Thus, it is
plausible that there are functional cholesterol sites
close to the lipid–protein interface. Indeed, an-
drostanol shows a small statistical preference for the
lipid–protein interface relative to phosphatidyl-
w xcholine, where it occupies some ;38 sites 24 .
Putative cholesterol sites on the nAcChoR have been
explored in homology modeling studies based on the
structure of membrane permeablizing toxins whose
structures are known in their soluble form. In one
model based on the structure of myohemerythrin,
which has four sequentially connected antiparallel
a-helices, the known structure was built into a pen-
tamer around a central pore. The overlapping sub-
units left five grooves in the lipid–protein interface
w xof the correct size to accommodate cholesterol 45 .
A similar conclusion was reached in a more recent
w xstudy, based on a suggestion of Unwin 46 , that the
tertiary structure of the nAcChoR might be similar to
that of the B5 pentamer of the heat-labile enterotoxin
w xof E. coli 47 . Both these models suggest that the
putative cholesterol binding sites are in the lipid–pro-
tein interface and are exposed to the bilayer on one
face, a conclusion that is quite consistent with the
results obtained with our analogs. Thus, the hypo-
thetical cholesterol sites on the nAcChoR must be
more accessible to the bilayer than those in the
 2q 2q. w xCa –Mg -ATPase studied by Ding et al. 11 .
Recently, it has been suggested that extramembra-
neous regions of the receptor are involved in the
binding of the spin-labeled androstane because the
motionally restricted component of the spectra is lost
when the extramembraneous portion of the nAcChoR
w xare digested 48 . If this hypothesis is true, our results
would suggest that such cholesterol sites must be
very close to the bilayer. However, such a vigorous
digestion is likely to have perturbed subunit–subunit
interactions and alternative interpretations are possi-
ble.
A precedent for low affinity but specific lipid
modulation of a multisubunit protein is provided by
 . w xD-b-hydroxybutyrate dehydrogenase BDH 49 .
Upon reconstitution, activity was only restored if
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phosphatidylcholine was present in the bilayer. Half
maximal activation occurred at 18 mol% phos-
phatidylcholine with a Hill coefficient of 2.4. These
figures may be compared to those for cholesterol’s
action on the nAcChoR of 10 mol% and 1.9. BDH is
thought to have one phosphatidylcholine per subunit,
and the similarity of the activation isotherms suggests
that something similar might be the case for the
nAcChoR.
4.4. Possible models of cholesterol’s action
The kinetics of activation cannot be studied in
detail because they are too rapid for stopped flow
techniques; therefore, it is not possible to distinguish
between a model where cholesterol must be bound to
its sites before activation can occur, and a model
where cholesterol plays a more dynamic role such as
reducing the activation energy of channel opening.
The exchange rate of androstanol between the bilayer
and the lipid–protein interface is likely to be compa-
rable to that of other spin-labeled lipids on the nAc-
 6 y1. w xChoR )10 s 50 . Thus, it should be able to
exchange during gating, making a dynamic role plau-
sible. An interesting new hypothesis invokes the me-
chanical properties of the membrane in much the
same way as the flip-flop model did; only here, the
bending strain might be relieved by cholesterol dif-
fusing laterally into its binding sites that are only
 .exposed during the conformation change Fig. 5b .
This model demands that the annular sites be asym-
metrical with respect to the bilayer, and that they be
in rapid exchange with the bilayer, concepts that are
open to experimental test.
4.5. Conclusions
Our data are consistent with the hypothesis that
cholesterol sites exist on the nAcChoR, and that they
must be involved in agonist-induced activation. The
new experimental conclusion is that these sites must
be in contact with the lipid bilayer, a conclusion that
is in accord with modeling studies noted above. In
this respect, the acetylcholine receptor differs from
 2q 2q. w xthe Ca –Mg -ATPase 11 . In the latter case, the
tethered cholesterol analog failed to act like choles-
terol, supporting the notion of interstitial sites well
separated from the bilayer. The terminology now
needs to be modified to allow a classification of
nonannular sites into interstitial and periannular,
where the latter are binding sites in crevices on the
surface of the protein that are open to the lipid
bilayer. The term annular sites still applies to the
remaining area on the lipid–protein interface, where
lipid motion is restricted on the EPR time scale
relative to that in the bilayer, and where only moder-
ate lipid selectivity may be observed.
The data all tend to point to the existence of
cholesterol sites, and the challenge is now to design
experiments capable of providing definitive proof of
their existence. In the meantime, it remains possible
that some unidentified property of the lipid–protein
interface is important. However, it is difficult to see
how any such model could account for the complete
lack of activation in the absence of cholesterol.
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